The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Chiasma, Inc. | Common | 16706W102 | 30,861 | 5,736,296 | SH | SOLE | 5,736,296 | 0 | 0 | ||
Harpoon Therapeutics, Inc. | Common | 41358P106 | 75,105 | 4,524,425 | SH | SOLE | 4,524,425 | 0 | 0 | ||
Repare Therapeutics, Inc. | Common | 760273102 | 93,177 | 3,003,772 | SH | SOLE | 3,003,772 | 0 | 0 | ||
Rhythm Pharmaceuticals, Inc. | Common | 76243J105 | 42,576 | 1,909,258 | SH | SOLE | 1,909,258 | 0 | 0 | ||
Syndax Pharmaceuticals, Inc. | Common | 87164F105 | 32,140 | 2,168,691 | SH | SOLE | 2,168,691 | 0 | 0 | ||
TCR2 Therapeutics, Inc. | Common | 87808K106 | 62,221 | 4,050,865 | SH | SOLE | 4,050,865 | 0 | 0 |